RYSTIGGO is UCB's FcRn-targeting monoclonal antibody therapy that lowers IgG levels in adults with gMG.
Competing Products
UCB
Belgium-based UCB SA is a global biopharmaceutical firm specializing in CNS disorders and inflammatory diseases.
Belgium-based UCB SA is a global biopharmaceutical firm specializing in CNS disorders and inflammatory diseases.
UCB is a global biopharmaceutical company headquartered in Brussels, Belgium. The company focuses on developing innovative solutions for people living with neurological and autoimmune conditions. UCB's mission is to create valuable treatments that improve the lives of patients, driven by the belief that everyone deserves to live their best life possible.
As a leader in the biopharmaceutical industry, UCB specializes in the treatment of central nervous system disorders and inflammatory diseases. The company works closely with patients, caregivers, and healthcare professionals to forge strong connections and deliver impactful solutions. UCB's approach combines scientific expertise with a patient-centric focus, aiming to make meaningful improvements in the lives of those affected by these conditions.
Companies similar to UCB include Cyrus Biotechnology, Exeltis, Lundbeck and Sanofi.
UCB was founded in 1928.
UCB's headquarters is located in City of Brussels, Flemish Brabant, BE.
UCB's most recent funding round was for €94.5M (EUR) in May 2022.
As of May 24, 2022, UCB has disclosed funding of $202.1M (USD). Undisclosed round amounts are excluded.
UCB has 7,600 employees as of Feb 6, 2024.
Cyrus Biotechnology
cyrusbio.com
Exeltis
exeltis.com
Lundbeck
lundbeck.com
Sanofi
sanofi.com
Bristol Myers Squibb
bms.com
Novartis
novartis.com
Supernus Pharmaceuticals
supernus.com
AstraZeneca
astrazeneca.com
Lonza
lonza.com
Biogen
biogen.com
Ipsen
ipsen.com
PTC Therapeutics
ptcbio.com
AbbVie
abbvie.com
Amylyx Pharmaceuticals
amylyx.com
Catalyst Pharmaceuticals
catalystpharma.com